BioSpace News Archive

Actinium Pharmaceuticals, Inc. today highlighted updated survival data from its Phase 1b trial evaluating Actimab-A in combination with the salvage chemotherapy CLAG-M in patients with high-risk relapsed or refractory acute myeloid leukemia (r/r AML) and new preclinical data with Actimab-A in combination with FLT3 inhibitors at the Society of Hematologic Oncology (SOHO) 2023 Annual Meeting.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of five upcoming scientific presentations on its investigational drug LX9211, which is being evaluated in clinical trials for the treatment of diabetic peripheral neuropathic pain (DPNP).

Daxor Corporation announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11 - 13, 2023 at the Lotte New York Palace.

A new prospective, multicenter study, recently published in The Lancet Neurology has revealed the significant prognostic value of the Neurological Pupil index™ (NPi®), measured using the NeurOptics NPi Pupillometer, in evaluating disease progression and predicting outcomes for patients with acute brain injury.

Catalent, Inc. today announced that members of its executive leadership team will participate at two upcoming investor conferences.

Sentynl herapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, announced that data evaluating NULIBRY® (fosdenopterin) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A were presented at the 2023 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Meeting on Aug. 30 in Jerusalem.

Scipher Medicine Corporation today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), and Centers for Medicare and Medicaid Services (CMS) published a local coverage determination (LCD) for molecular biomarker testing to guide targeted therapy selection in rheumatoid arthritis (RA) patients.

Acupath Labs a leading provider of sub-specialized anatomic and molecular pathology services, launches the BioFire® FilmArray® GI Panel, a FDA-cleared PCR based panel that tests for 22 of the most common pathogens associated with gastroenteritis, with results in ~ 1 hour.

Dr. Abdel Halim, Acutis Biosciences’ Chief Scientific Officer, one of a group who led the study FOENIX-CCA2 (funded by Taiho Oncology and Taiho Pharmaceutical), recently published results about Futibatinib (LYTGOBI®) in cholangiocarcinoma with FGFR2 gene rearrangements/fusions in the New England Journal of Medicine (NEJM).

Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will participate in the following investor conferences in September: